海大集团(002311) - 2024年12月4日投资者关系活动记录表

Group 1: Overseas Operations - The company's overseas feed sales exceeded 100,000 tons in the first half of the year, with a year-on-year growth of over 30% [1] - The company has established core production capacities in Southeast Asia, South America, and Africa, and is expanding into neighboring markets with ongoing construction of new factories [1] Group 2: Team Structure and Capacity - The overseas team is expanding through a combination of domestic assignments and local recruitment, with a focus on accelerating team development [2] - The overall capacity for overseas production is currently tight, prompting the company to actively expand its capacity layout in relevant regions [2] Group 3: Business Diversification - The company's overseas business includes aquatic feed, livestock feed, animal health products, and breeding bases, leveraging its expertise across the supply chain to enhance competitive advantages [2] - The demand for meat protein is growing in regions like Southeast Asia, Africa, and Latin America, driving the expansion of the feed industry [2] Group 4: Future Outlook - The global shrimp market is experiencing growth, with stable demand and potential price increases during holidays, particularly around the Spring Festival [2] - The company is exploring a light-asset, low-risk, and stable pig farming model, continuously refining the optimal scale for this approach [2] Group 5: Raw Material Trends - The prices of bulk raw materials are generally declining, with future trends heavily influenced by macroeconomic factors [5] Group 6: Capital Expenditure Plans - Future capital expenditures will focus on overseas capacity construction and expansion, while domestic investments will prioritize upgrading and renovating existing capacities [7] Group 7: Animal Health Business - The decline in animal health product revenue in the first half of the year is attributed to the integration of many health products into feed, creating functional feed products that replace traditional standalone health products [6]